Skip to main content
Have a personal or library account? Click to login
Toxicological aspects of the use of phenolic compounds in disease prevention Cover

Toxicological aspects of the use of phenolic compounds in disease prevention

By:   
Open Access
|Feb 2012

References

  1. Agte V and Tarwadi K. (2010). The importance of nutrition in the prevention of ocular disease with special reference to cataract.(3): 166-172.
  2. Ahmad A, Asad SF, Singh S and Hadi SM. (2000). DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation.: 29-37.
  3. Angelone T, Pasqua T, Di Majo D, Quintieri AM, Filice E, Amodio N, Tota B, Giammanco M and Cerra MC. (2010). Distinct signalling mechanisms are involved in the dissimilar myocardial and coronary effects elicited by quercetin and myricetin, two red wine flavonols.(5): 362-371.
  4. Baraldo M. (2008). The influence of circadian rhytms on the kinetics of drugs in humans.(2): 175-192.
  5. Barjesteh van Waalwijk van Doorn-Khosrovani S, Janssen J, Maas LM, Godschalk RW, Nijhuis JG and Schooten FJ. (2007). Dietary flavonoids induce MLL translocations in primary human CD34+ cells.: 1703-1709.
  6. Bhat KPL and Pezzuto JM. (2002). Cancer chemopreventive activity of resveratrol.: 210-229.
  7. Birt DF, Hendrich S and Wang WQ. (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids.: 157-177.
  8. Biswal SS, Datta K, Shaw SD, Feng X, Robertson JD and Kehrer JP. (2000). Glutathione oxidation and mitochondrial depolarization as mechanisms of nordihydroguaiaretic acid-induced apoptosis in lipoxygenase-deficient FL5.12 cells.: 77-83.
  9. Brazier NC, Mitchell AH and Levine MD. (2003). Understanding drug-herb interaction.: 427-430.
  10. Brown JP. (1980). A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds.: 243-277.
  11. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E and Grever MR. (1998). Flavopiridol induces apoptosis in chronic lymphocytic leukemia cellsactivation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.: 3804-3816.
  12. Canivenc-Lavier MC, Bentejac M, Leclerc MH, Siess MH, Latruffe N and Suschetet M. (1996). Differential effects of nonhydroxylated flavonoids as inducers of cytochrome P450 1A and 2B isozymes in rat liver.: 348-353.
  13. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY and Kwok TT. (2001). Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells.: 1207-1214.
  14. Colalto C. (2010). Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment.: 207-227.
  15. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L and Vlietinck AJ. (2003). Phytoestrogens: recent developments.: 589-599.
  16. Crozier A, Del Rio D and Clifford MN. (2010). Bioavailability of dietary flavonoids and phenolic compounds.(6): 446-467.
  17. Csokay B, Prajda N, Weber G and Olah E. (1997). Molecular mechanisms in the antiproliferative action of quercetin.: 2157-2163.
  18. Cvorovic J, Tramer F, Granzotto M, Candussio L, Decorti G and Passamonti S. (2010). Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells.: 151-157.
  19. Decker EA. (1997). Phenolics: pro-oxidants or antioxidants?: 396-407.
  20. Degli Esposti M. (1998). Inhibitors of NADH-ubiquinone reductase: an over-view. Biochim Biophys Acta: 222-235.
  21. Doostdar H, Burke MD and Mayer RT. (2000). Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1.: 31-38.
  22. Duffy C, Perez K and Partridge A. (2007). Implications of phytoestrogen intake for breast cancer.: 260-277.
  23. Dunnick JK and Hailey JR. (1992). Toxicity and carcinogenicity studies of quercetin, a natural component of foods.: 423-431.
  24. Duthie GG, Gardner PT and Kyle JA. (2003). Plant polyphenols: are they the new magic bullet?: 599-603.
  25. EMEA Commitee on Herbal Medicinal Products. (2006). Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for well-estabilished and of community herbal monographs/entries to the community list for traditional herbal medicinal products/substances/preparations. Avaible from:
  26. Fang N and Casida JE. (1998). Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH: ubiquinone oxidoreductase and induced ornithine decarboxylase activities.: 3380-3384.
  27. Feng R, Ni HM, Wang SY, Tourkova IL, Shurin MR, Harada H and Yin XM. (2007). Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress.: 13468-13476.
  28. Ferguson LR and Philpott M. (2008). Nutrition and mutagenesis.: 313-329.
  29. Fischer PM and Lane DP. (2000). Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.: 1213-1245.
  30. Formica JV and Regelson W. (1995). Review of the biology of quercetin and related bioflavonoids.: 1061-1080.
  31. Fraga CG, Galleano M, Verstraeten SV and Oteiza PI. (2010). Basic biochemical mechanisms behind the health benefits of polyphenols.: 435-445.
  32. Franconi F, Brunelleschi S, Steardo L and Cuomo V. (2007). Gender differences in drug responses.(2): 81-95.
  33. Fuhr U. (1998). Drug interactions with grapefruit juice. Extent, probablemechanism and clinical relevance.(4): 251-272.
  34. Furukawa A, Oikawa S, Murata M, Hiraku Y and Kawanishi S. (2003). (_)-Epigallocatechin gallate causes oxidative damage to isolated and cellular DNA.: 1769-1778.
  35. Galati G and O'Brien PJ. (2004). Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties.(3): 287-303.
  36. Galati G, Sabzevari O, Wilson JX and O'Brien PJ. (2002). Pro-oxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics.: 91-104.
  37. Gerwirtz DA. (1991). Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?: 2253-2258.
  38. Ghosh D and Konishi T. (2007). Anthocyanins and anthocyanin-rich extracts: role in diabetes and eye function.(2): 200-208.
  39. Gill WB. (1988). Effects on human males of in utero exposure to exogenous sex hormones, in(Mori T and Nagasawa H eds) pp. 161-177, CRC, Boca Raton, FL.
  40. Goldstein JC, Waterhouse P, Juin P, Evan GI and Green DR. (2000). The coordinate release of cytochrome c is rapid, complete, and kinetically invariant.: 156-162.
  41. Guarrera S, Sacerdote C, Fiorini L, Marsala R, Polidoro S, Gamberini S, Saletta F, Malaveille C, Talaska G, Vineis P and Matullo G. (2007). Expression of DNA repair and metabolic genes in response to a flavonoid-rich diet.: 525-533.
  42. Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Their R, Coles B and Harris TM. (1994). Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes.: 49-53.
  43. Hadi SM, Asad SF, Singh S and Ahmad A. (2000). Putative mechanism for anticancer and apoptosis-inducing properties of plantderived polyphenolic compounds.: 167-171.
  44. Halliwell B. (2007). Dietary polyphenols: good, bad, or indifferent for your health?: 341-347.
  45. Halliwell B. (2008). Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture andstudies?(2): 107-112.
  46. Halliwell B. (2009). The wanderings of a free radical.: 531-542.
  47. Hirose M, Fukushima S, Sakata T, Inui M and Ito N. (1983). Effect of quercetin on two-stage carcinogenesis of the rat urinary bladder.: 23-27.
  48. Hodek P, Hanustiak P, Krizkova J, Mikelova R, Krizkova S, Stiborova M, Trnkova L, Horna A, Beklova M and Kizek R. (2006). Toxicological aspects of flavonoid interaction with biomacromolecules.(Suppl 2): 14-17.
  49. Hodek P, Trefil P and Stiborova M. (2002). Flavonoids—potent and versatile biologically active compounds interacting with cytochromes P450.: 1-21.
  50. Hou DX, Ose T, Lin S, Harazoro K, Imamura I, Kubo M, Uto T, Terahara N, Yoshimoto M and Fujii M. (2003). Anthocyanidins induce apoptosis in human promyelocytic leukemia cells: structure-activity relationship and mechanisms involved.: 705-712.
  51. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, Kandaswami C, Middleton EJr and Lee MT. (1999). Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.: 999-1010.
  52. Ibrahim AR and Abul-Hajj YJ. (1990). Aromatase inhibition by flavonoids.: 257-260.
  53. Ito N, Hagiwara A, Tamano S, Kagawa M, Shibata MA, Kurata Y and Fukushima S. (1989). Lack of carcinogenicity of quercetin in F334/DuCrj rats.: 317-325.
  54. Izzo AA and Ernst E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review.(15): 2163-2175.
  55. Jaganatah IB and Crozier A. (2010). Dietary flavonoids and phenolic compounds, in Plant Phenolics and Human Health (Fraga CG ed), pp. 1-50, John Wiley & Sons Inc., Hoboken, NJ.
  56. Jaganathan SK and Mandal M. (2009). Antiproliferative effects of honey and of its polyphenols: a review.: 830616.
  57. Kalt W, Hanneken A, Milbury P and Tremblay F. (2010). Recent research on polyphenolics in vision and eye health.: 4001-4007.
  58. Katdare M, Jinno H, Osborne MP and Telang NT. (1999). Negative growth regulation of oncogene-transformed human breast epithelial cells by phytochemicals: role of apoptosis.: 247-252.
  59. Kellis JT and Vickery LE. (1984). Inhibition of human estrogen synthetase (aromatase) by flavones.: 1032-1034.
  60. Kim JS, He L and Lemasters JJ. (2003). Mitochondrial permeability transition: a common pathway to necrosis and apoptosis.: 463-470.
  61. Klejdus B, Mikelova R, Petrlova J, Potesil D, Adam V, Stiborova M, Hodek P, Vacek J, Kizek R and Kuban V. (2005). Evaluation of isoflavone aglycon and glycoside distribution in soy plants and soybeans by fast column high-performance liquid chromatography coupled with a diode-array detector.: 5848-5852.
  62. Knekt P, Kumpulainen J, Järvinen R, Rissanen H, Heliövaara M, Reunanen A, Hakulinen T and Aromaa A. (2002). Flavonoid intake and risk of chronic diseases.(3): 560-568.
  63. Kohn MC, Walker NJ, Kim AH and Portier CJ. (2001). Physiological modeling of a proposed mechanism of enzyme induction by TCD.: 193-208.
  64. Kong AN, Yu R, Chen C, Mandlekar S and Primiano T. (2000). Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis.(1): 1-16.
  65. Kroemer G. (2003). Mitochondrial control of apoptosis: an introduction.: 433-435.
  66. Kuo SM. (1996). Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells.: 41-48.
  67. Lockwood B. (2008). The beneficial effects of soy isoflavones in osteoporosis of the elderly.(5): 38-41.
  68. Makela S, Poutanen M, Kostian ML, Lehtimaki N Strauss L, Santti R and Vihko R. (1998). Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.(3): 310-316.
  69. Messina M and Wood CE. (2008). Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary.(1): 17-28.
  70. Messina M, McCaskill-Stevens W and Lampe JW. (2006). Addressing the soy and breast cancer relatioship: review, commentary, and workshop proceedings.(18): 1275-1284.
  71. Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E and Segura-Aguilar J. (1999). Quercetin may act as a cytotoxic pro-oxidant after its metabolic activation to semiquinone and quinoidal product.(1-2): 107-116.
  72. Miadokova E. (2009). Isoflavonoids - an overview of their biological activities and potential health benefits.(4): 211-218.
  73. Middleton E and Kandaswami C. (1994). The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, in(Harborne JB ed) pp. 619-652, Chapman & Hall, London.
  74. Miksicek RJ. (1995). Estrogenic flavonoids: structural requirements for biological activity.: 44-50.
  75. Miniello VL, Moro GE, Tarantino M, Natile M, Granieri L and Armenio L. (2003). Soy-based formulas and phyto-oestrogens: a safety profile.: 93-100.
  76. Morino K, Matsukura N, Kawachi T, Ohgaki H, Sugimura T and Hirono I. (1982). Carcinogenicity test of quercetin and rutin in golden hamsters by oral administration.: 93-97.
  77. Newbold RR, Banks EP, Bullock B and Jefferson WN. (2001). Uterine adenocarcinoma in mice treated neonatally with genistein.(11): 4325-4328.
  78. Ni H, Simile C, and Hardy AM. (2002). Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey.: 353-358.
  79. Omiecinski CJ, Remmel RP and Hosagrahara VP. (1999). Concise review of the cytochrome P450s and their roles in toxicology.: 151-156.
  80. Oyama Y, Noguchi S, Nakata M, Okada Y, Yamazaki Y, Funai M, Chikahisa L and Kanemaru K. (1999). Exposure of rat thymocytes to hydrogen peroxide increases annexin V binding to membranes: inhibitory actions of deferoxamine and quercetin.: 47-52.
  81. Pamukcu AM, Yalciner S, Hatcher JF and Bryan GT. (1980). Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (: 3468-3472.
  82. Panes J, Gerritsen ME, Anderson DC, Miyasaka M and Granger DN. (1996). Apigenin inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation: 279-286.
  83. Paschka AG, Butler R and Young CY. (1998). Induction of apoptosis in prostate cancer cell lines by the green tea component, (_)-epigallocatechin-3-gallate.(1-2): 1-7.
  84. Patil BS, Jayaprakasha GK, Chidambara Murthy KN and Vikram A. (2009). Bioactive compounds: historical perspectives, opportunities, and challenges.(18): 8142-8160.
  85. Rahman A, Shahabuddin A, Hadi SM and Parish JH. (1990). Complexes involving quercetin, DNA and Cu(II).(11): 2001-2003.
  86. Rhone M and Basu A. (2008). Phytochemicals and age-related eye diseases.(8): 465-472.
  87. Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME and Alink GM. (2005). Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk.(1-2): 124-138.
  88. Rietjens IM, Huseiny WA, Boersma MG. (2011). Flavonoids and alkenylbenzenes: New concepts in bioactivation studies.(1-2): 87-95.
  89. Rietjens IM, Slob W, Galli C and Silano V. (2008). Risk assessment of botanical preparations intended for use in food and food supplements: emerging issues.(2): 131-136.
  90. Rong Y, Yang EB, Zhang K and Mack P. (2000). Quercetin-induced apoptosis in the monoblastoid cell line U937and the regulation of heat shock proteins expression.: 4339-4345.
  91. Ross JA. (1998). Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors?: 26-28.
  92. Ross JA and Kasum CM. (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety.: 19-34.
  93. Ross JA, Potter JD and Robison LL. (1994). Infant leukemia, topoisomerase II inhibitors, and the MLL gene.: 1678-1680.
  94. Russo M, Palumbo R, Tedesco I, Mazzarella G, Russo P, Iacomino G and Russo GL. (1999). Quercetin and anti-CD95(Fas/ Apo1) enhance apoptosis in HPBALL cell line.: 322-328.
  95. Rzymowska J, Gawron A, Pawlikowska-Pawlega B, Jakubowicz-Gil J and Wojcierowski J. (1999). The effect of quercetin on induction of apoptosis.: 125-126.
  96. Sakihama Y, Cohen MF, Grace SC and Yamasaki H. (2002). Plant phenolic antioxidant and pro-oxidant activities: phenolics-induced oxidative damage mediated by metals in plants.: 67-80.
  97. Scalbert A and Williamson G. (2000). Dietary intake and bioavailability of polyphenols.: 2073S-2085S.
  98. Schewe T, Steffen Y and Sies H. (2008). How do dietary flavanols improve vascular function? A position paper.(2): 102-106.
  99. Schilter B, Andersson C, Anton R, Constable A, Kleiner J, O'Brien J, Renwick AG, Korver O, Smit F and Walker R. (2003). Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements.(12): 1625-1649.
  100. Schroeter H, Spencer JP, Rice-Evans C and Williams RJ. (2001). Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3.: 547-557.
  101. So FV, Guthrie N, Chambers AF, Moussa M and Carroll KK. (1996). Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices.: 167-181.
  102. Soriani M, Rice-Evans C and Tyrrell RM. (1998). Modulation of the UVA activation of haem oxygenase, collagenase and cyclooxygenase gene expression by (_)-epigallocatechin in human skin cells.: 253-257.
  103. Spencer JP, Rice-Evans C and Williams RJ. (2003a). Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and itsmetabolites underlie their action on neuronal viability.(37): 34783-34793.
  104. Spencer JP, Kuhnle GG, Williams RJ and Rice-Evans C. (2003b). Intracellular metabolism and bioactivity of quercetin and itsmetabolites.: 173-181.
  105. Steiner C, Peters WH, Gallagher EP, Magee P, Rowland I and Pool-Zobel BL. (2007). Genistein protects human mammary epithelial cells from benzo(a) pyrene-7,8-dihydrodiol-9,10-epoxide and 4-hydroxy-2-nonenal genotoxicity by modulating the glutathione/glutathione S-transferase system.: 738-748.
  106. Strick R, Strissel PL, Borgers S, Smith SL and Rowley JD. (2000). Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia.: 4794-4795.
  107. Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G and Lee SJ. (1999). Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells.: 1-10.
  108. Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V and Mukhtar H. (2008). Delphinidin inhibits cell proliferation and invasionmodulation of Met receptor phosphorylation.(1): 52-60.
  109. Takamura-Enya T, Ishihara J, Tahara S, Goto S, Totsuka T, Sugimura T and Wakabayashi K. (2003). Analysis of estrogenic activity of foodstuffs and cigarette smoke condensates using a yeast estrogen screening method.: 543-550.
  110. Talavera S, Felgines C, Texier O, Besson C, Gil-Izquierdo A, Lamaison JL and Remesy C. (2005). Anthocyanin metabolism in rats and their distribution to digestive area, kidney, and brain.: 3902-3908.
  111. Tang DG and Porter AT. (1996). Apoptosis: a current molecular analysis.: 117-131.
  112. Tang W and Stearns RA. (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug - drug interactions.: 185-198.
  113. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.: 401-407.
  114. Terada T and Inui K. (2007). Gene expression and regulation of drug transporter in the intestine and kidney.: 440-449.
  115. Ueda S, Nakamura H, Masutani H, Sasada T, Takabayashi A, Yamaoka Y and Yodoi J. (2001). Baicalin induces apoptosis via mitochondrial pathway as pro-oxidant.: 781-791.
  116. van der Woude H, Gliszczynska-Swiglo A, Struijs K, Smeets A, Alink GM and Rietjens IM. (2003). Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans.: 41-47.
  117. Walle T, Vincent TS and Walle UK. (2003). Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells.: 1603-1610.
  118. Waller CL and McKinney JD. (1995). Three-dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds: model validation and Ah receptor characterization.: 847-858.
  119. Wang IK, Lin-Shiau SY and Lin JK. (1999). Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells.: 1517-1525.
  120. Wang LS and Stoner GD. (2008). Anthocyanins and their role in cancer prevention.: 281-290.
  121. Wang Y, Gho WM, Chan FL, Chen S and Leung LK. (2008). The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression.: 303-310.
  122. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K and Uchida A. (1994). Induction of apoptosis by quercetin: involvement of heat shock protein.: 4952-4957.
  123. Wenzel U, Kuntz S, Brendel MD and Daniel H. (2000). Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells.: 3823-3831.
  124. Williams RJ, Spencer JP and Rice-Evans C. (2004). Flavonoids: antioxidants or signalling molecules?(7): 838-849.
  125. Woodward G, Kroon P, Cassidy A and Kay C. (2009). Anthocyanin stability and recovery: implications for the analysis of clinical and experimental samples.: 5271-5278.
  126. Yamanaka A, Oda O and Nagao S. (1997). Green tea catechins such as (_)-epicatechin and (_)-epigallocatechin accelerate Cu-induced low density lipoprotein oxidation in propagation phase.: 230-234.
  127. Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS. (1998). Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols.: 611-616.
  128. You L, Sar M, Bartolucci EJ, McIntyre BS and Sriperumbudur R. (2002). Modulation of mammary gland development in prepubertal male rats exposed to genistein and methoxychlor.: 216-225.
  129. Ziberna L, Lunder M, Moze S, Vanzo A, Tramer F, Passamonti S and Drevensek G. (2010). Acute cardioprotective and cardiotoxic effects of bilberry anthocyanins in ischemia-reperfusion injury: beyond concentration-dependent antioxidant activity.(4): 283-94.
DOI: https://doi.org/10.2478/v10102-011-0027-5 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Language: English
Page range: 173 - 183
Published on: Feb 6, 2012
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services

© 2012 Zuzana Kyselova, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.